Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8651761 | The American Journal of the Medical Sciences | 2018 | 13 Pages |
Abstract
Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sohail Abdul MD, Lakshmi Ramachandran MD, Litty MD, Vishnu MD, Venkataraman MD, Mohit MD, Tibor MD,